Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.74 |
| ▸ | TAS2R14 | Q9NYV8 | 13/20 | 0.72 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.72 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | CNR2 | P34972 | 1/20 | 0.69 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.64 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863697 | 0.90 | CXCR3 (0.69) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1278788 | 0.86 | TAS2R14 (0.97) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1278616 | 0.84 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1169926 | 0.84 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1278846 | 0.84 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1169636 | 0.83 | CXCR3 (1.00) | PTGESTAS2R14CXCR3TAS2R8CNR2 | |
| SCHEMBL1279281 | 0.82 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1169654 | 0.82 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1279497 | 0.82 | TAS2R14 (1.00) | PTGESTAS2R14CXCR3TAS2R8MEN1 | |
| SCHEMBL1169679 | 0.82 | TAS2R14 (0.78) | PTGESTAS2R14CXCR3TAS2R8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| EP-2265575-A2 | SULFONAMIDES | Merck Serono S.A. (CH) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124962-A2 | SULFONAMIDES | MERCK SERONO S.A. (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | PTGES 746/4885TAS2R14 517/4885CXCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.